Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Biotech investors sometimes overlook companies solving fundamental drug development problems. Entrada Therapeutics (NASDAQ: TRDA ) operates in one such space, solving the enduring problem of intracellular drug delivery. Although much of the sector is under capital constraints andI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My ...